Analysis of therapeutic response onset time in thyroid cancer patients treated by lenvatinib
Not Applicable
Recruiting
- Conditions
- Thyroid cancer
- Registration Number
- JPRN-UMIN000019484
- Lead Sponsor
- Ito Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Thyroid cancer patients who treat by lenvatinib but can't follow CT imagings regularly.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Characterization of tumor size changes of 2,4,6,8,12,16,20 and 24 weeks after medication.
- Secondary Outcome Measures
Name Time Method Improved response rate, time to first objective response, efficacy, changes of CT imaging, association with thyroglobulin, clinical factors of good responders.